A synthetic peptide for use as a blocking control in assays to test for specificity of SSX2 antibody, Alternative Names: SSX2 control peptide, SSX2 antibody Blocking Peptide, Anti-SSX2 Blocking Peptide, synovial sarcoma, X breakpoint 2 Blocking Peptide, HD21 Blocking Peptide, HOM-MEL-40 Blocking Peptide, MGC119055 Blocking Peptide, MGC15364 Blocking Peptide, MGC3884 Blocking Peptide, SSX Blocking Peptide, SSX2, SSX-2, SSX 2, SSX-2 Blocking Peptide, SSX 2 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
SSX2
(Synovial Sarcoma, X Breakpoint 2 (SSX2))
Hintergrund
SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.